Cancer uses a sort of “cellular camouflage”, tricking the immune system into seeing it as a normal cell. Dan Chen, M.D., Ph.D., global head of development for cancer immunotherapies at Genentech, explains how immunotherapy may affect the PD-L1/PD-1 pathway, enabling the body to better detect and fight cancer.